Custom stealth-functionalized lipid nanoparticle development for reduced nonspecific biological interactions, improved colloidal stability, controlled surface shielding, payload-compatible formulation, and application-specific delivery research.
Stealth-functionalized lipid nanoparticles (LNPs) are engineered with hydrophilic or biomimetic surface components that reduce unwanted interactions with proteins, phagocytic cells, and other biological components. Conventional designs rely on PEG-lipids, while emerging approaches use cleavable PEG layers, polysarcosine (pSar), zwitterionic polymers, poly(2-oxazoline)s, polyglycerol, or biomimetic surface architectures. These materials create hydrated or sterically protected interfaces that can improve nanoparticle stability and alter circulation and biodistribution behavior.
Effective stealth design requires more than maximizing surface shielding. Excessive polymer density can reduce cellular association, interfere with targeting-ligand accessibility, and limit membrane interactions needed for intracellular payload release. Conversely, a loosely anchored or rapidly shedding coating may provide insufficient protection in biological media. Polymer chemistry, chain length, surface density, lipid anchor, linker structure, LNP composition, and payload therefore need to be optimized together.
BOC Sciences provides integrated nanoparticle surface functionalization services for PEG-based and PEG-free stealth LNP development. We support stealth material selection and synthesis, LNP formulation, surface incorporation, physicochemical characterization, serum and protein-interaction studies, cellular evaluation, and formulation troubleshooting for RNA, proteins, peptides, small molecules, and other research payloads.
Schematic of Stealth Surface-Modified LNPsStealth functionalization modifies the outer LNP interface to reduce nonspecific interactions with proteins, phagocytic cells, and other biological components. Hydrophilic polymers such as PEG, polysarcosine, poly(2-oxazoline), and polyglycerol form hydrated steric barriers; zwitterionic materials create strongly hydrated charge-balanced surfaces; and biomimetic coatings reproduce selected features of natural membranes. The appropriate strategy depends on the target tissue, payload, administration route, and whether the shielding layer should remain stable or be removed during delivery.
PEG contains a flexible, highly hydrophilic polyether chain. In PEG-lipids, the hydrophobic anchor remains associated with the LNP while PEG extends into the aqueous phase. This hydrated polymer layer creates steric hindrance that reduces aggregation, nonspecific protein adsorption, opsonization, and phagocytic recognition. Stealth performance depends strongly on PEG chain length, surface density, conformation, and anchor retention.
Cleavable and shedding PEG systems provide temporary rather than permanent steric shielding. PEG is connected through a stimulus-sensitive linker or lipid anchor with controlled desorption. The PEG layer protects the LNP during initial exposure to biological fluids, then cleavage or anchor dissociation reduces the surface barrier and can restore membrane interaction, ligand accessibility, cellular uptake, or intracellular delivery.
Polysarcosine (pSar) is a hydrophilic polypeptoid composed of N-methylated glycine units. Its flexible backbone interacts strongly with water and forms a hydrated steric layer around the LNP. Because pSar has a different backbone from PEG, pSar-lipids are investigated as PEG-free stealth materials for reducing nonspecific protein interactions while maintaining colloidal stability and cellular delivery.
Zwitterionic polymers contain both positive and negative groups while maintaining an approximately neutral overall charge. Carboxybetaine-, sulfobetaine-, and phosphorylcholine-based structures strongly bind water and form dense hydration layers that make protein displacement of surface-bound water less favorable. This low-fouling interface can reduce nonspecific protein adsorption and provides a PEG-free stealth strategy.
Poly(2-oxazoline)s (POx) have hydrophilic amide-rich backbones whose side-chain chemistry can tune polarity and hydration, while linear polyglycerol (lPG) contains multiple hydroxyl groups that form a strong hydration shell. When linked to lipid anchors, both polymers create water-rich surface layers that suppress nonspecific interactions and provide PEG-alternative stealth behavior.
Biomimetic stealth systems reproduce selected features of natural cell surfaces instead of relying only on synthetic polymer brushes. Cell-derived membranes contain phospholipids, proteins, glycans, and other native components that can retain selected self-recognition or immune-interaction properties. When used as the outer nanoparticle interface, they may reduce nonspecific immune recognition while also providing tissue tropism or homotypic recognition.
Tell us your payload, target tissue, administration route, and the biological interaction you want to reduce. BOC Sciences can compare PEG, PEG-free polymers, responsive coatings, and biomimetic surface strategies for your LNP design.
Our service portfolio covers stealth material chemistry, nanoparticle assembly, surface analysis, and biological-interaction testing. Each work package can be performed individually or combined into a comparative development program, depending on the client's payload, dosing plan, and stage of formulation research.
We design and prepare the stealth conjugates that a project needs, rather than limiting clients to a single catalog polymer.
We identify how the stealth component should be introduced—during particle formation or afterward on preformed LNPs—and how much of it the surface should carry.
The stealth layer and the LNP core are optimized together so that circulation benefits are not gained at the expense of payload loading or intracellular delivery.
We quantify both the particle and its stealth layer, so that biological results can be interpreted against known surface properties.
Stealth performance is defined by biological media, not by clean buffers. We test how candidate surfaces behave under serum-containing conditions.
We refine preparation and post-processing variables so that stealth-LNP batches remain comparable across independent preparations.
A well-designed stealth layer changes how an LNP interacts with its environment. The benefits below depend on polymer choice, density, and the biological setting, so comparative testing remains essential.
Reduced Nonspecific Protein Adsorption
The hydrated corona formed by PEG or PEG-alternative polymers sterically repels opsonins, lowering the first step of MPS recognition. This makes biodistribution easier to interpret and reduces unexplained batch-to-batch variability in uptake assays.
Improved Stability in Biological Media
Stealth layers limit particle–particle fusion and aggregation in serum-containing environments and during storage. Combined with appropriate lipid composition, they help maintain size, PDI, and payload retention between preparation and use.
Tunable Circulation and Biodistribution
Polymer length, surface density, and anchor structure provide multiple levers for adjusting how long a particle circulates and where it accumulates. Screening these variables together identifies the compromise that fits a specific delivery route and tissue goal.
Flexible Balance Between Shielding and Delivery
Cleavable PEG designs, ligand-compatible end groups, and PEG-free alternatives allow the shield to be weakened where and when uptake is needed. This flexibility is what allows stealth and targeting functions to coexist on one particle.
BOC Sciences develops stealth-modified LNPs for many payload classes used in long-circulating delivery research. Each payload needs a suitable loading strategy, particle design, and functional readout, and we match the stealth surface engineering to both the payload and the intended cell model.
| Payload Type | Supported Uses & Stealth-LNP Development Considerations | Request Information |
|---|---|---|
| Stealth-LNP Development for mRNA | Designed for protein-expression, reporter, and repeat-dose formulation studies. Development considers mRNA integrity, encapsulation, stealth-layer shielding of uptake, and expression readouts in selected cell models. Related work is supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Stealth-LNP Development for siRNA | Suitable for gene-silencing studies where circulation time and target-cell access both matter. We evaluate siRNA encapsulation, free-RNA reduction, stealth density, and knockdown against matched unmodified controls, building on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Stealth-LNP Development for circRNA and saRNA | Applicable to RNA systems needing strong payload protection and sustained expression. Stealth compatibility with lipid nanoparticles for circRNA delivery and saRNA delivery is verified through stability and cell-based expression testing. | Inquiry |
| Stealth-LNP Development for ASO and miRNA | Supports antisense and microRNA payloads requiring stable long-circulating carriers. We consider loading chemistry, stealth-layer interference with uptake, and functional silencing endpoints, drawing on our work in lipid nanoparticles for ASO delivery and miRNA delivery. | Inquiry |
| Stealth-LNP Development for CRISPR RNP | Designed for gene-editing research platforms such as lipid nanoparticles for CRISPR RNP delivery, where editing components require protection in circulation and efficient release after uptake. We evaluate co-loading behavior, stealth density, and functional editing readouts. | Inquiry |
| Stealth-LNP Development for Protein and Peptide | Suitable for protein antigens, enzymes, and functional protein payloads used in long-circulating delivery research, with mild loading conditions and aggregation control informed by our protein encapsulation in LNPs capabilities. | Inquiry |
| Stealth-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules in lipid nanoparticles for small molecule delivery research. We consider drug–lipid compatibility, leakage control, stealth modification, and release behavior. | Inquiry |
| Stealth-LNP Development for Fluorescent and Imaging | Supports labeled RNA, labeled proteins, and tracking payloads used to study circulation kinetics and distribution trends. Our fluorescent-labeled lipid nanoparticles capabilities apply directly to stealth-LNP tracking studies. | Inquiry |
| Stealth-LNP Development for Custom Payload | Developed for unusual payloads, multiple-payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, stealth modification route, particle stability, and target-cell delivery performance. | Inquiry |
Tell us your payload, dosing plan, and delivery goal, and BOC Sciences will propose a stealth surface strategy that fits your project.
A stealth-LNP can look well formed in buffer yet still fail in serum or in a repeat-dose study. We investigate formulation and biological factors together and use comparison studies to identify the step limiting performance.
√ Excessive Protein Adsorption and Opsonization
Dense, well-hydrated stealth layers can still adsorb proteins if coverage is patchy or the polymer layer is too thin. We compare surface density, polymer length, and anchor retention, and quantify bound protein to identify a coating design that actually reduces corona formation.
√ Rapid Phagocytic Uptake and Clearance
Particles that disappear into liver and spleen macrophage models rarely reach their target. We combine corona profiling with macrophage-uptake comparisons and matched unmodified controls to determine whether clearance is driven by surface chemistry, aggregation, or size.
√ PEG-Related Immune Recognition
For programs affected by anti-PEG responses, we screen PEG-free stealth routes (pSar, zwitterionic, POx, poly(glycerol)) in parallel, using immune-interaction assays supported by LNP safety assessment workflows to compare candidates under matched conditions.
√ Excessive Shielding and Poor Cellular Uptake
A stealth layer that is too dense or too persistent blocks the membrane contact needed for internalization. We map stealth density against internalization using nanoparticle cellular uptake testing, then adjust density, anchor, or shedding design to restore uptake while keeping stability.
√ Premature Surface Polymer Shedding
Short or poorly matched lipid anchors can desorb from the particle before it reaches its target, silently converting a stealth LNP into a bare one. We track anchor retention through serum exposure and storage as part of lipid nanoparticle stability studies and re-select anchors when retention is insufficient.
√ Reduced Endosomal Escape and Payload Activity
The same shield that blocks opsonins can block endosomal membrane disruption. We compare intracellular localization and reporter or silencing readouts, with optional LNP endosomal escape evaluation, to determine whether the bottleneck is uptake or escape and act on the correct parameter.
Tell us whether the bottleneck is opsonization, phagocytic uptake, PEG-related immune recognition, surface shedding, or endosomal escape. BOC Sciences can design a focused troubleshooting study using matched formulations and clear analytical readouts.
Projects can begin with a client's existing formulation, an identified stealth material, or only a delivery objective. We organize the work into four practical stages, refining the plan as formulation and biological evidence becomes available.
We review the payload class, intended route of laboratory exposure, dosing plan (single or repeated), baseline formulation if available, and desired biological readouts. Circulation-time targets, comparator models, and acceptable particle attributes help define the starting materials and screening plan.
We select the polymer family (PEG, cleavable PEG, pSar, zwitterionic, POx/poly(glycerol), or biomimetic), chain length, anchor structure, and incorporation route. Ligand compatibility, matched unmodified controls, and the assays that will verify surface coverage are defined at this stage.
Candidate particles are prepared by controlled mixing, and stealth density, lipid ratios, and purification conditions are screened systematically. During LNP process optimization, we adjust flow conditions, stealth-lipid input, and buffer exchange, then compare size, PDI, surface coverage, and payload retention before advancing candidates.
We assess selected candidates in serum-containing media and in the agreed cell or research models: protein corona, serum stability, macrophage uptake, and payload-specific functional endpoints. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
Stealth-functionalized LNPs are useful when the delivery objective requires controlled interaction with biological fluids, reduced nonspecific cellular recognition, or a tunable transition between protected circulation and productive cell entry.
Hydrated surface layers can be optimized to reduce rapid particle recognition and investigate longer systemic exposure. Candidate formulations can be compared using circulation measurements and nanoparticle in vivo distribution analysis to determine how polymer chemistry, density, and anchor retention influence organ-level distribution.
PEG-free and modified-stealth surfaces can be compared when a research program requires multiple administrations or repeated exposure to the same carrier. Studies may examine whether particle properties, antibody interactions, biological distribution, and payload activity remain consistent across the selected experimental sequence.
Stealth layers can reduce nonspecific interactions during systemic exposure while leaving sufficient surface flexibility for accumulation and cellular interaction within selected disease models. For tumor-related projects, stealth design can be incorporated into tumor-targeted LNP development together with surface-ligand and intracellular-delivery optimization.
A stealth polymer and an active targeting ligand can be presented on the same nanoparticle, but the two functions must be balanced. Excessive shielding may hide the ligand, whereas insufficient shielding can increase nonspecific uptake. Our targeted LNP development approach evaluates ligand accessibility, stealth density, cellular recognition, and payload function together.
Challenge: A research team was developing an eGFP-mRNA LNP for a protein-replacement research program requiring weekly administration to a small-animal model. Their initial formulation used a high PEG-lipid fraction (2.5 mol%) with a long-chain C18 anchor: circulation was long, but reporter expression was weak and macrophage uptake in in vitro models was low. Reducing PEG to 0.5 mol% restored expression but caused serum aggregation and rapid loss of the payload from circulation, so no single formulation satisfied both requirements.
Diagnosis: BOC Sciences found that the dense, highly persistent PEG corona was over-shielding the particle—suppressing both cellular uptake and endosomal escape—while the low-PEG variant lacked a stable surface layer in serum. Batch-to-batch PDI variation also traced back to insufficiently controlled mixing conditions.
Solution: We screened a 3 × 3 matrix of PEG-lipid fraction (1.0, 1.5, and 2.0 mol%) against anchor structure (C14, C16, and C18-based PEG-lipids) in otherwise matched four-component formulations, using controlled microfluidic mixing. Candidates were compared for size, PDI, mRNA encapsulation, serum stability over 24 h, bound-protein levels, macrophage uptake, and eGFP expression in HEK293 and primary-cell models before the repeat-administration comparison.
Result: The selected candidate used 1.5 mol% PEG-lipid with a C16 anchor, giving an average size of about 85 nm, PDI below 0.15, and mRNA encapsulation near 90%. Compared with the over-shielded starting formulation, expression improved roughly 2.5-fold, while serum stability and circulation behavior remained clearly superior to the low-PEG variant. Reporter expression stayed consistent across four weekly administrations. The client received a balanced lead formulation plus a defined PEG-density window for future development.
Challenge: A biotechnology group was delivering siRNA against an inflammatory-pathway target in a macrophage-related tumor model. Their PEGylated siRNA-LNP performed well after the first administration, but knockdown dropped sharply after the second and third doses, and accelerated blood clearance was suspected. They needed a PEG-free stealth formulation that preserved silencing activity.
Diagnosis: BOC Sciences confirmed that repeat exposure to the PEGylated candidate was associated with faster clearance of subsequent doses, consistent with an anti-PEG-related ABC-type response, rather than with payload instability or RNA degradation.
Solution: We prepared matched siRNA formulations carrying three PEG-free stealth components—a polysarcosine-lipid, a zwitterionic PCB-lipid, and a polyoxazoline-lipid—and compared them with the original PEG-lipid candidate. Screening covered particle attributes, encapsulation, serum stability, protein corona, macrophage uptake, and target knockdown, followed by sequential-administration comparison in the relevant model.
Result: The pSar-based candidate (about 100 nm, PDI below 0.20, siRNA encapsulation near 85%) maintained target knockdown of about 65–70% across repeated administrations, while the PEGylated comparator lost most of its activity after the second dose. The pSar-LNP also showed lower inflammatory-cytokine release in a human whole-blood assay. The client obtained an ABC-resistant lead candidate and a documented comparison of three PEG-free stealth routes for their program.
End-to-End Stealth LNP Development SupportStealth material synthesis, surface engineering, formulation, characterization, and biological evaluation are handled within one coordinated plan, reducing the disconnect between polymer chemistry and particle performance.
Multiple PEG and PEG-Free Stealth StrategiesClassic, cleavable, and PEG-alternative routes are all available for direct comparison, so material selection is driven by project data rather than by catalog limitations.
Mechanism-Based Surface OptimizationDensity, chain length, and anchor decisions are made against measured opsonization, uptake, and shedding data, so improvements reflect the actual mechanism limiting each formulation.
Protein Corona and Functional Delivery EvaluationCorona profiling, serum stability, macrophage uptake, and payload-function readouts are connected to surface design, helping teams avoid candidates that look stable but deliver poorly.
Application-Specific Formulation ScreeningScreening plans are built around the payload, dosing schedule, and model system of each project, giving teams practical comparative data for candidate selection and next-step decisions.
A stealth LNP is engineered to reduce nonspecific interactions with proteins, opsonins, and phagocytic cells through surface modification rather than through a single defining material. Hydrophilic polymers such as PEG, polysarcosine, poly(2-oxazoline), and polyglycerol can form hydrated steric barriers, while zwitterionic materials create strongly hydrated, charge-balanced interfaces. Stealth behavior also depends on polymer chain length, surface density, lipid anchor, and shedding kinetics. BOC Sciences can optimize these variables together with the underlying LNP formulation to balance biological shielding, colloidal stability, cellular interaction, and functional payload delivery.
PEG alternatives being investigated for LNP surface engineering include polysarcosine (pSar), poly(2-oxazoline)s and poly(2-oxazine)s, polyglycerols, and zwitterionic polymers such as PMPC and PCB. Biomimetic coatings and structurally modified PEG systems provide additional options. These materials are not interchangeable because each can differently affect hydration, protein-corona formation, particle assembly, biodistribution, and intracellular trafficking. BOC Sciences can compare multiple PEG-free polymer-lipid structures under matched formulation conditions to identify candidates that provide useful surface shielding while maintaining payload encapsulation, particle stability, cellular uptake, and functional delivery.
Stealth material selection should consider the payload, core lipid composition, target tissue, administration route, repeated-exposure requirements, and whether an active targeting ligand must remain accessible. Polymer molecular weight, surface density, lipid anchor, linker structure, and shedding behavior can all alter protein adsorption and productive cellular interactions. A persistent coating may suit projects requiring prolonged shielding, whereas cleavable or shedding surfaces may be preferable when membrane interaction must increase after distribution. BOC Sciences can screen PEG, pSar, polyoxazoline, polyglycerol, and zwitterionic polymer systems and connect surface chemistry with serum stability, uptake, and payload-specific performance.
Stealth performance should not be inferred from particle size or nominal polymer content alone. A useful evaluation combines size, PDI, zeta potential, surface-polymer incorporation, serum stability, and protein-corona analysis with biological readouts such as macrophage uptake, target-cell association, intracellular localization, endosomal escape, and payload function. When relevant to the research model, circulation and biodistribution comparisons can provide additional information about surface behavior. BOC Sciences integrates physicochemical characterization with protein-interaction and functional delivery assays so that researchers can determine whether a surface modification genuinely improves the nano-bio interface or simply increases steric shielding.
Yes. Excessive or highly persistent surface shielding can reduce the same membrane interactions required for productive cellular uptake and intracellular delivery. Dense PEG or other hydrophilic polymer layers may also mask targeting ligands and interfere with endosomal membrane interactions. In contrast, insufficient shielding can increase protein adsorption, phagocytic recognition, and premature clearance. The objective is therefore not maximum stealth, but an application-specific balance between protection and delivery. Polymer-density optimization, shorter or differently anchored polymer-lipids, cleavable PEG, and controlled shedding strategies can be used to adjust this balance.
